Physician profile
Abdullah M Khalid
NPI 1811239981
$2,465.63
in general payments reported to CMS, 2019-2025
14 companies · $94.47 in 2025
The $94.47 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $131 · 2021: $26.99 · 2022: $22.04 · 2023: $20.35 · 2024: $1,972 · 2025: $94.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,148 · Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,148.10 |
| Food and Beverage | $939.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,747.17 | 2024-2025 | Inspire |
| Zoll Respicardia, INC. | $177.99 | 2024 | Remede System |
| Abbvie INC. | $126.45 | 2021-2024 | |
| Allergan, INC. | $88.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $75.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.30 | 2019-2020 | |
| Lilly USA, LLC | $25.09 | 2025 | Zepbound |
| Abbott Laboratories | $22.04 | 2022 | |
| Servier Pharmaceuticals LLC | $22.01 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $18.79 | 2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $18.78 | 2025 | |
| Eisai INC. | $18.71 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.